Triumph are proud to release the following position paper: Designing Risk Detection Metrics for Risk-Based Monitoring
Triumph are proud to release the following position paper:
Designing Risk Detection Metrics for Risk-Based Monitoring
To download Triumph's position paper, please click on the link to the Triumph website and go to the Risk-Based Monitoring page: http://www.triumphconsultancy.co.uk/
Triumph are going to be presenting their approach and new operational system, Visual OPRA, at the CBI Risk-Based Monitoring in Clinical Studies 2013 conference October 24-25, Philadelphia, PA.
For more info on the CBI conference please visit our Events page on our website at www.triumphconsultancy.co.uk, or contact us as at [email protected]
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.